← Gilead Sciences

What podcasts say about Gilead Sciences

Every statement, with the speaker, the exact quote and the moment it was said.

What experts have said about Gilead Sciences

8 statements · 7 positive · 1 mixed

  1. Daniel CliftonPositiveNov 6, 2026· The Compound and Friends

    Gilead’s hepatitis C cure will save Medicare hundreds of billions of dollars.

    “They are going to save Medicare hundreds of billions of dollars.”

    Listen at 7:10

    Open the episode · You Ain’t Seen Nothing Yet with Daniel Clifton
  2. Yaron WerberMixedNov 6, 2026· Biotech Hangout

    Gilead’s anito-cel is expected to be less effective but safer than Legend’s product.

    “I think it's expected that the Gilead product won't be quite as effective, but a lot safer.”

    Listen at 58:46

    Open the episode · Episode 202 - November 6, 2026
  3. Geoff MeachamPositiveOct 26, 2026· Closing Bell

    Gilead Sciences could perform well in the third quarter.

    “that, I think, could do quite well for 3Q.”

    Listen at 35:53

    Open the episode · Closing Bell Overtime: Markets Face a Big Week as AI Takes Center Stage 10/26/26
  4. Gilead is currently actionable for investors

    “I think it's a stock that is actionable right here”

    Listen at 23:13

    Open the episode · Nasdaq, Small Caps Hit On AI Worries, Pesky Inflation: Dell, GILD, THC In Focus
  5. Gilead operates across oncology and immunology in addition to HIV and hepatitis C

    “they're also in oncology, some forms of cancer, and also immunology”

    Listen at 24:07

    Open the episode · Nasdaq, Small Caps Hit On AI Worries, Pesky Inflation: Dell, GILD, THC In Focus
  6. Gilead is expected to return to profitability in 2027

    “going to ramp back up to profitability in 2027”

    Listen at 24:37

    Open the episode · Nasdaq, Small Caps Hit On AI Worries, Pesky Inflation: Dell, GILD, THC In Focus
  7. Gilead may outperform in 2027

    “we'll see if Gilead can be a nice outperformer in 2027”

    Listen at 25:26

    Open the episode · Nasdaq, Small Caps Hit On AI Worries, Pesky Inflation: Dell, GILD, THC In Focus
  8. Jim CramerPositiveApr 15, 2026· Mad Money w/ Jim Cramer

    Investors should continue holding Gilead Sciences.

    “I'd hold on to it.”

    Listen at 38:36

    Open the episode · Mad Money w/ Jim Cramer 4/15/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.